Table 1.
The only significant difference (p<0.05) is that patients with CRSwNP compared to CRSsNP, and those with eCRS compared to neCRS, are more likely to have used oral corticosteroids two weeks before surgery.
| CRSsNP (n=29) n (%) |
CRSwNP (n=28) n (%) |
neCRS (n=30) n (%) |
eCRS (n=27) n (%) |
All Patients n (%) |
|
|---|---|---|---|---|---|
| Eosinophilic | 6 (20.7%) | 21 (75.0%) | 27 (100%) | 27 (47.4%) | |
| Nasal Polyps | 28 (100%) | 7 (23.3%) | 21 (77.8%) | 28 (49.1%) | |
| Female | 18 (62.1%) | 12 (42.9%) | 19 (63.3%) | 11 (40.7%) | 30 (52.6%) |
| Prior ESS | 4 (13.8%) | 8 (28.6%) | 4 (13.3%) | 8 (29.6%) | 12 (21.1%) |
| Atopy by skin/blood tests | 14 (48.3%) | 13 (46.4%) | 16 (53.3%) | 11 (40.7%) | 27 (47.4%) |
| Asthma | 9 (31.0%) | 10 (35.7%) | 9 (30.0%) | 10 (37.0%) | 19 (33.3%) |
| Aspirin Allergy | 2 (6.9%) | 4 (14.3%) | 1 (3.3%) | 5 (18.5%) | 6 (10.5%) |
| Smoker | 5 (17.2%) | 6 (21.4%) | 6 (20.0%) | 5 (18.5%) | 11 (19.3%) |
| Oral Steroid | 1 (3.4%) | 7 (25.0%) | 2 (6.7%) | 6 (22.2 %) | 8 (14.0%) |
| Nasal Steroid | 8 (27.6%) | 5 (17.9%) | 7 (23.3%) | 6 (22.2%) | 13 (22.8%) |
| Age (x̄, s2) | (46.7, 16.5) | (45.9, 11.5) | (48.8,14.9) | (43.2, 13.3) | (46.3, 14.3) |
Abbreviations: CRS with polyps (CRSwNP); CRS without polyps (CRSsNP); noneosinophilic CRS (neCRS); eosinophilic CRS (eCRS); endoscopic sinus surgery (ESS). Percentages are expressed as the percent of each column.